Vincent Ribrag
- Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment 180
- Oncology top 0.5%
- CAR-T cell therapy research 59
- Viral-associated cancers and disorders 39
- Cancer Immunotherapy and Biomarkers 36
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 70
- Hematology top 1%
- Multiple Myeloma Research and Treatments 26
- Immunology top 2%
-
- CNS Lymphoma Diagnosis and Treatment 26
-
- Protein Degradation and Inhibitors 26
- Co-authors
- Jean‐Marie MichotPier Luigi ZinzaniCraig H. MoskowitzPhilippe ArmandMargaret A. ShippArun BalakumaranPauline BriceBastian von Tresckow
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Vincent Ribrag
300 papers receiving 7.8k citations
Hit Papers
Peers
Comparison fields: 5 of 111
- Pathology and Forensic Medicine 3.6k
- Oncology 4.6k
- Genetics 1.7k
- Hematology 962
- Immunology 1.5k
Countries citing papers authored by Vincent Ribrag
This map shows the geographic impact of Vincent Ribrag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Ribrag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Ribrag more than expected).
Fields of papers citing papers by Vincent Ribrag
This network shows the impact of papers produced by Vincent Ribrag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Ribrag. The network helps show where Vincent Ribrag may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Vincent Ribrag, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 4 | |
| 3 | 2023 | 0 | |
| 4 | 2023 | 7 | |
| 5 | 2023 | 2 | |
| 6 | 2022 | 3 | |
| 7 | 2022 | 12 | |
| 8 | 2021 | 19 | |
| 9 | 2020 | 54 | |
| 10 | 2020 | 63 | |
| 11 | 2019 | 128 | |
| 12 | 2018 | 106 | |
| 13 | Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphomabreakdown → | 2017 | 694 |
| 14 | 2017 | 47 | |
| 15 | 2017 | 18 | |
| 16 | 2016 | 237 | |
| 17 | 2015 | 94 | |
| 18 | 2013 | 79 | |
| 19 | 2012 | 188 | |
| 20 | 2008 | 25 |
About Vincent Ribrag
Vincent Ribrag is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hematology and Cancer Research, having authored 309 papers that have together received 7.9k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (180 papers), Chronic Lymphocytic Leukemia Research (70 papers), CAR-T cell therapy research (59 papers), Viral-associated cancers and disorders (39 papers), Cancer Immunotherapy and Biomarkers (36 papers), CNS Lymphoma Diagnosis and Treatment (26 papers), Multiple Myeloma Research and Treatments (26 papers) and Protein Degradation and Inhibitors (26 papers). The work is most often cited by research in Pathology and Forensic Medicine (3.6k citations), Oncology (4.6k citations), Genetics (1.7k citations), Hematology (962 citations) and Immunology (1.5k citations). Vincent Ribrag has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Jean‐Marie Michot, Pier Luigi Zinzani, Craig H. Moskowitz, Philippe Armand, Margaret A. Shipp, Arun Balakumaran, Pauline Brice, Bastian von Tresckow, John Radford and Jean‐Charles Soria. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.